Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno- Oncology Biomarker Working Group on Breast Cancer - Université Clermont Auvergne Accéder directement au contenu
Article Dans Une Revue Seminars in Cancer Biology Année : 2018

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno- Oncology Biomarker Working Group on Breast Cancer

Susan Fineberg
Gert van den Eynden
  • Fonction : Auteur
Timothy M d'Alfonso
  • Fonction : Auteur
Sandra Demaria
Joselyn Sanchez
  • Fonction : Auteur
Sunil Badve
Stefan Michiels
Veerle Bossuyt
  • Fonction : Auteur
Federico Rojo
  • Fonction : Auteur
Baljit Singh
  • Fonction : Auteur
Torsten Nielsen
  • Fonction : Auteur
Giuseppe Viale
  • Fonction : Auteur
Seong-Rim Kim
  • Fonction : Auteur
Stephen Hewitt
Stephan Wienert
  • Fonction : Auteur
Sybille Loibl
  • Fonction : Auteur
David Rimm
Fraser Symmans
  • Fonction : Auteur
Carsten Denkert
Sylvia Adams
  • Fonction : Auteur
Sherene Loi
Roberto Salgado

Résumé

Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

Domaines

Cancer
Fichier principal
Vignette du fichier
015 Update on TIL Evaluation in BC ... (Dieci, Radosevic-Robin et al, Semin Cancer Biology 2018).pdf (615.97 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-02387991 , version 1 (30-11-2019)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Maria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, Gert van den Eynden, Nils Ternes, et al.. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno- Oncology Biomarker Working Group on Breast Cancer. Seminars in Cancer Biology, 2018, 52, pp.16 - 25. ⟨10.1016/j.semcancer.2017.10.003⟩. ⟨hal-02387991⟩
193 Consultations
151 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More